Call for Abstract

8th International Conference on Epilepsy & Treatment, will be organized around the theme “Seizures and Epilepsy: An Overview for Neuroscientists”

Epilepsy 2022 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Epilepsy 2022

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

The Ketogenic Diet (KD) is a modality of treatment used since the 1920s as a treatment for intractable epilepsy. The Ketogenic diet is a special high-fat, low-carbohydrate diet that helps to control seizures in some people with epilepsy. It is usually used in children with seizures that do not respond to medications. Evidence shows that KD and its variants are a good alternative for non-surgical pharmacoresistant patients with epilepsy of any age.

  • Track 1-1Classic Ketogenic Diet
  • Track 1-2Medium chain triglyceride (MCT) diet
  • Track 1-3Ketone Bodies: Anticonvulsant Effects
  • Track 1-4Low Glycaemic Index Treatment (LGIT)

The coronavirus COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War Two. Since its emergence in Asia late last year, the virus has spread to every continent except Antarctica. There is no evidence that having epilepsy alone makes people more likely to catch coronavirus or have more severe symptoms.

However, epilepsy is a very varied condition. Some people with epilepsy have other conditions alongside their epilepsy, which may put them at increased risk. Anyone with a compromised immune system or on-going medical challenges may have a higher risk of complications. The US Centers for Disease Control and Prevention (CDC) has included epilepsy on a list of conditions that may increase the risk of serious COVID-19 infection, likely because it is a chronic neurological condition. The UK has included people with chronic neurological conditions (without specifying epilepsy) as an “at risk” group.

  • Track 2-1COVID-19
  • Track 2-2Epileptic Seizures
  • Track 2-3Epilepsy Management
  • Track 2-4Seizure Control

Epilepsy is a chronic non communicable and Neurological disorder of the brain that affects people of all ages. Epilepsy occurs when brain activity becomes abnormal, causing seizures. Seizures can affect any process your brain coordinates. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.

  • Track 3-1Tonic-clonic seizures
  • Track 3-2Focal seizures
  • Track 3-3Generalized seizures
  • Track 3-4Absence seizures

Epilepsy is a chronic disorder with diverse clinical characteristics that preclude a singular mechanism a neurological disorder marked by sudden recurrent episodes of seizures. A seizure occurs when part of the brain receives a burst of abnormal electrical signals that temporarily interrupts normal electrical brain function. It is one of the most common disorders of the nervous system and affects people of all ages, races, and ethnic background. The fact that multiple mechanisms exist is not surprising given the varied ways the normal nervous system controls this balance. In contrast, understanding seizures in brain of an individual with epilepsy is more difficult because seizures are typically superimposed on an altered nervous system.


  • Track 4-1Birth trauma
  • Track 4-2Alcohol or Drugs
  • Track 4-3Brain tumor
  • Track 4-4Neurological problems
  • Track 4-5Stroke

Epileptogenesis is the chronic process by which a normal brain develops epilepsy. Epilepsy is a chronic condition in which seizures occur. These changes to the brain occasionally cause neurons to fire in a hyper-synchronous manner, known as a seizure. Epileptogenesis can be triggered by genetic or acquired factors, and that can continue long after epilepsy diagnosis.

  • Track 5-1Traumatic brain injury (TBI)
  • Track 5-2Stroke
  • Track 5-3Cerebral Tumour
  • Track 5-4Intracranial Hemorrhage
  • Track 5-5Status Epilepticus
  • Track 5-6Seizures
  • Track 5-7Epilepsy

Emotional distress is common in people with epilepsy (PWE) for which efficacious interventions are required. Developing evidence-based treatments should be based on testable models of the psychological mechanisms maintaining Psychopathology. The Self-Regulatory Executive Function (S-REF) model proposes that maladaptive Metacognitive beliefs and processes are central to the development and maintenance of emotional distress. Although preliminary support exists for the role of metacognitive beliefs in emotional distress in PWE, their role has yet to be tested when controlling for the contribution made by illness perceptions.


  • Track 6-1Anxiety
  • Track 6-2Depression

Epilepsy is not a mental illness. In fact, the vast majority of people living with epilepsy have no cognitive or psychological problem. For the most part, psychological issues in epilepsy are limited to people with severe and uncontrolled epilepsy.

  • Track 7-1Epilepsy and Intellectual Disability
  • Track 7-2Epilepsy and Depression
  • Track 7-3Epilepsy and Cognitive Disorders
  • Track 7-4Epilepsy and Anxiety
  • Track 7-5Epilepsy and Behavioural Issues

Epilepsy can begin at any time of life, but it is most commonly diagnosed in children and people over the age of 65. More than half of children with epilepsy will outgrow their seizures as they mature, while others may have seizures that continue into adulthood. Although epilepsy varies from person to person, children with epilepsy generally have seizures that respond well to medication. Epilepsy affects around 1 in every 200 children and young people under 18 Children having idiopathic. About two-thirds of all children with epilepsy outgrow their seizures by the time they are teenagers. However, it is important for parents to help their child maintain a healthy lifestyle and ensure regular medical visits.


  • Track 8-1Febrile convulsions
  • Track 8-2Childhood absence epilepsy
  • Track 8-3Epilepsy in gender & age
  • Track 8-4Seizures in childhood
  • Track 8-5Attention Deficit Hyperactivity Disorder (ADHD)

Women with epilepsy have a number of unique concerns during pregnancy. Pregnant women with epilepsy constitute 0.5% of all pregnancies. Some antiepileptic drugs considered safe to the foetus may be associated with increased risk of seizures and maternal mortality. Factors such as epilepsy, anticonvulsant-induced teratogenicity, patient's genetic predisposition and the severity of convulsive disorder may attribute to adverse pregnancy outcome for the children of women with epilepsy.


  • Track 9-1Epilepsy during Pregnancy
  • Track 9-2Anti-epileptic drugs
  • Track 9-3Pregnancy and Motherhood
  • Track 9-4Brain infections

Medications can control seizures in most people with epilepsy, but they don’t work for everyone. About 30% of people taking the drugs can’t tolerate the side effects. A person's type of seizures and where they begin in the brain are key to deciding what kind of surgery may help. Surgery has three main goals, they are Remove the area of the brain that causes seizures, Disrupt the nerve pathways that seizure impulses take through your brain, Implant a device to treat epilepsy. An operation on the brain can control seizures and improve your quality of life.


  • Track 10-1Focal Resection
  • Track 10-2Lobectomy
  • Track 10-3Multiple Subpial Transection
  • Track 10-4Hemispherectomy
  • Track 10-5Corpus callosotomy
  • Track 10-6Stereotactic Radiosurgery
  • Track 10-7Neurostimulation Device Implantations

Seizure medicines do not control seizures or can cause bothersome side effects in at least 3 out of 10 people with epilepsy. Seizure alert devices are useful in letting family members know if a seizure is occurring, especially parents of young children. The devices can notify nearby family or caregivers when a seizure occurs through alarms, phone calls or text alerts, depending on the device. They may also be able to give rescue medications or call for an ambulance if the seizure lasts too long or the person has repeated seizures.


  • Track 11-1Vagus Nerve Stimulation
  • Track 11-2Seizure Alarms
  • Track 11-3Medic Alert bracelet
  • Track 11-4Anti-suffocation pillows
  • Track 11-5Mattress devices
  • Track 11-6Cameras
  • Track 11-7Smart watches


Doctors have developed when an individual experience a seizure for the first time doctors advices him for EEG and observes for abnormality in the of  EEG these tests differentiate patient from epileptic to non- epileptic. Research suggests that patients are only suggested to medicated for epilepsy only after their  occurrence of second seizure. Many non-epileptic patients experience an unusual brain activity so; it is advised to record EEG while sleeping is preferable. Brain scans like CT- SCAN are used.


  • Track 12-1EEG
  • Track 12-2CT SCAN
  • Track 12-3Positron Emission Tomography (PET)
  • Track 12-4Magnetic Resonance Imaging (MRI)
  • Track 12-5Single Photon Emission Tomography
  • Track 12-6Magneto Encephalogram
  • Track 12-7MRS
  • Track 12-8Medical history
  • Track 12-9Blood tests

Sudden Unexpected Death in Epilepsy (SUDEP) is a fatal complication of epilepsy. SUDEP accounts for 7–17% of deaths among people with epilepsy. This is the leading cause of death in people with uncontrolled seizures. Patients with uncontrolled seizures are at greatest risk for SUDEP, and experiencing tonic-clonic seizures, taking multiple antiepileptic drugs and having coexisting neurologic disease further increase the risk.


  • Track 13-1Uncontrolled or Frequent Seizures
  • Track 13-2Generalized Convulsive Seizures
  • Track 13-3Epilepsy in Childhood
  • Track 13-4Missed doses of medicine
  • Track 13-5Missed doses of medicine
  • Track 13-6Alcohol or Drugs


The interest in Cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered Placebo-controlled, Randomized trials (RCTs) with Cannabidiol (CBD), a cannabis derivative.